1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
PharmGen Science, Inc.

PharmGen Science, Inc.

004720.KS
PharmGen Science, Inc.KR flagKorea Exchange
3,115.00
KRW
-50.00
- -
56.57BMarket Cap

Total Valuation

PharmGen Science, Inc. carries a market capitalization of 56.57B, placing it among publicly traded companies globally. Its enterprise value stands at 58.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap56.57B
Enterprise Value58.26B

Valuation Ratios

PharmGen Science, Inc. trades at a trailing price-to-earnings ratio of 32.77. The price-to-sales ratio is 0.41, and the price-to-book ratio stands at 2.34.

PE Ratio32.77
PS Ratio0.41
PB Ratio2.34
P/TBV Ratio0.50
P/FCF Ratio4.96
P/OCF Ratio5.81

Enterprise Valuation

On an enterprise value basis, PharmGen Science, Inc. trades at an EV/EBITDA multiple of 10.20 and an EV/FCF ratio of 3.66. The EV/Sales ratio of 0.34 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.20 provides insight into valuation relative to core operating earnings.

EV / Sales0.34
EV / EBITDA10.20
EV / EBIT10.20
EV / FCF3.66

Financial Position

PharmGen Science, Inc. maintains a current ratio of 2.90, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Current Ratio2.90
Quick Ratio0.59
Debt / Equity4.09
Debt / EBITDA1.08
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-134.08
Return on Assets (ROA)-43.36
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.93

Taxes

Income Tax-34.58B
Effective Tax RateN/A

Stock Price Statistics

PharmGen Science, Inc.'s stock has declined approximately -27.47381% over the past 52 weeks. The 50-day moving average sits at 3,422.90, while the 200-day moving average is 3,902.03.

Beta (5Y)N/A
52-Week Price Change-27.47381%
50-Day Moving Average3,422.90
200-Day Moving Average3,902.03
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, PharmGen Science, Inc. generated 173.52B in revenue and converted that into -116.92B in net income, yielding earnings per share of -5,428.77. EBITDA reached 5.71B, while operating income came in at 5.71B.

Revenue173.52B
Gross Profit113.39B
Operating Income5.71B
Pretax Income-151.50B
Net Income-116.92B
EBITDA5.71B
EBIT5.71B
Earnings Per Share (EPS)-5,428.77

Balance Sheet

PharmGen Science, Inc. holds 18.94B in cash and equivalents against 6.14B in total debt, resulting in a net debt position of -12.91B. Total book value stands at 30.33B, with working capital of 60.61B providing operational flexibility.

Cash & Cash Equivalents18.94B
Total Debt6.14B
Net Debt-12.91B
Equity (Book Value)30.33B
Book Value Per Share1,564.59
Working Capital60.61B

Cash Flow

PharmGen Science, Inc. produced 12.23B in operating cash flow over the past twelve months. After subtracting -3.68B in capital expenditures, free cash flow totaled 8.55B - equivalent to 440.99 per share.

Operating Cash Flow12.23B
Capital Expenditures-3.68B
Free Cash Flow8.55B
FCF Per Share440.99

Margins

PharmGen Science, Inc. operates with a gross margin of 65.35, reflecting its pricing power and cost economics. The operating margin of 3.29 and net profit margin of -67.38 provide insight into operational efficiency.

Gross Margin65.35
Operating Margin3.29
Pretax Margin-87.31
Profit Margin-67.38
EBITDA Margin3.29

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-0.22
FCF Yield20.16

Stock Splits

PharmGen Science, Inc.'s most recent stock split took place on December 9, 2014 with a 10:1 split ratio.

Last Split Date12/9/2014
Split Ratio10:1

Scores

PharmGen Science, Inc. posts an Altman Z-Score of 2.40, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.40